韩国五大药企上半年营收4.5万亿韩元 新药收入或决定下半年表现

格隆汇
Aug 04
据韩媒,韩国五大制药企业上半年合计销售额达到4.5万亿韩元。授权收入和海外业务成为拉开业绩差距的关键因素。随着韩国政府下调仿制药价格,市场预计,高利润创新药的表现将决定企业下半年的盈利情况。根据韩国金融监督院电子公示系统4日公布的数据,韩国五大制药企业——Yu han Corp.(裕韩)、Chong Kun Dang Pharmaceutical(钟根堂)、Hanmi Pharmaceutical(韩美制药)、GC绿十字以及Daewoong Pharmaceutical(大熊)——上半年合计售额为4.4996万亿韩元,营业利润为4106亿韩元。与去年同期相比,销售额增长8%,营业利润增长18%。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10